[1. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6:999-1009.10.1016/j.jcin.2013.05.017]Search in Google Scholar
[2. Maeng M, Tilsted HH, Jensen LO, et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORTOUT III study): a multicentre, open-label, randomised superiority trial. Lancet. 2014;383:2047-2056.10.1016/S0140-6736(14)60405-0]Search in Google Scholar
[3. Stone GW, Gao R, Kimura T, et al. 1-Year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277-1289.10.1016/S0140-6736(15)01039-9]Search in Google Scholar
[4. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.10.1161/01.CIR.78.5.1157]Search in Google Scholar
[5. Benedek T, Bucur O, Pașcanu I, Benedek I. Analysis of coronary plaque morphology by 64 multislice computed tomography coronary angiography and calcium scoring in patients with type 2 diabetes mellitus. Acta Endocrinologica. 2011;7:59-68.10.4183/aeb.2011.59]Search in Google Scholar
[6. Benedek I, Chitu M, Kovacs I, Bajka B, Benedek T. Incremental Value of preprocedural Coronary Computed Tomographic Angiography to classical Coronary Angiography for prediction of PCI complexity in left main stenosis. World Journal of Cardiovascular Disease. 2013;9:573-580.10.4236/wjcd.2013.39090]Search in Google Scholar
[7. Benedek T, Jako B, Benedek I. Plaque quantification by coronary CT and intravascular ultrasound identifies a low CT density core as a marker of plaque instability in acute coronary syndromes. Int Heart J. 2014:55:22-28.10.1536/ihj.13-21324463925]Search in Google Scholar
[8. Benedek T, Gyongyosi M, Benedek I. Multislice computed tomographic coronary angiography for quantitative assessment of culprit lesions in acute coronary syndromes. Can J Cardiol. 2013;29:364-371.10.1016/j.cjca.2012.11.00423333164]Search in Google Scholar
[9. Gogas BD, Serruys PW, Diletti R, et al. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimuseluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. JACC Cardiovasc Interv. 2012;5:656-665.10.1016/j.jcin.2012.02.01722721662]Search in Google Scholar
[10. Verheye S, Martinet W, Kockx MM, et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49:706-715.10.1016/j.jacc.2006.09.04717291937]Search in Google Scholar
[11. Ferent IF, Mester A, Hlinomaz O, et al. Intracoronary Imaging for Assessment of Vascular Healing and Stent Follow-up in Bioresorbable Vascular Scaffolds. Current Medical Imaging Reviews. 2018. [E-pub ahead of print.] doi: 10.2174/1573405614666180604093621.10.2174/157340561466618060409362132003312]Open DOISearch in Google Scholar
[12. Fajadet J, Haude M, Joner M, et al. Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016. EuroIntervention. 2016;12:828-833.10.4244/EIJV12I7A13727639734]Search in Google Scholar
[13. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144-1153.10.4244/EIJY14M07_1125042421]Search in Google Scholar
[14. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779-797.10.1161/CIRCULATIONAHA.110.971606]Search in Google Scholar
[15. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv. 2011;4:535-538.10.1161/CIRCINTERVENTIONS.111.96371022010192]Search in Google Scholar
[16. Bourantas CV, Garcia-Garcia HM, Diletti R, Muramatsu T, Serruys PW. Early detection and invasive passivation of future culprit lesions: a future potential or an unrealistic pursuit of chimeras? Am Heart J. 2013;165:869-881.10.1016/j.ahj.2013.02.015]Search in Google Scholar
[17. Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012;33:1325-1333.10.1093/eurheartj/ehr466]Search in Google Scholar
[18. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012;221:106-112.10.1016/j.atherosclerosis.2011.12.008]Search in Google Scholar
[19. Gomez-Lara J, Brugaletta S, Farooq V, et al. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc Interv. 2011;4:789-799.10.1016/j.jcin.2011.04.00921777888]Search in Google Scholar
[20. Lane JP, Perkins LE, Sheehy AJ, et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv. 2014;7:688-695.10.1016/j.jcin.2013.11.02424835327]Search in Google Scholar
[21. Serruys PW, Onuma Y. Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist’s jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS? EuroIntervention. 2017;12:2047-2056.10.4244/EIJY17M02_01]Search in Google Scholar
[22. James SK, Stenestrand U, Lindback J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med. 2009;360:1933-1945.10.1056/NEJMoa080990219420363]Search in Google Scholar
[23. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.10.1056/NEJMoa06772217296822]Search in Google Scholar
[24. Serruys PW, Daemen J. The SCAAR registry or the Swedish yo-yo. EuroIntervention. 2007;3:297-300.10.4244/EIJV3I3A5419737707]Search in Google Scholar